FT819 + Fludarabine + Cyclophosphamide + Bendamustine

Phase 1Recruiting

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)

Conditions

Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)

Trial Timeline

Mar 28, 2024 → Sep 30, 2042

NCT ID

NCT06308978

About FT819 + Fludarabine + Cyclophosphamide + Bendamustine

FT819 + Fludarabine + Cyclophosphamide + Bendamustine is a phase 1 stage product being developed by Fate Therapeutics for Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06308978. Target conditions include Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06308978	Phase 1	Recruiting	Mar 28, 2024	Sep 30, 2042	Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)